Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative Settings or with a Limitation of Life-Sustaining Therapies: A Systematic Review.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
25
7
2020
medline:
19
8
2021
entrez:
25
7
2020
Statut:
ppublish
Résumé
Refractory status epilepticus (RSE) represents a serious medical condition requiring early and targeted therapy. Given the increasing number of elderly or multimorbid patients with a limitation of life-sustaining therapy (LOT) or within a palliative care setting (PCS), guidelines-oriented therapy escalation options for RSE have to be omitted frequently. This systematic review sought to summarize the evidence for fourth-line antiseizure drugs (ASDs) and other minimally or non-invasive therapeutic options beyond guideline recommendations in patients with RSE to elaborate on possible treatment options for patients undergoing LOT or in a PCS. A systematic review of the literature in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, focusing on fourth-line ASDs or other minimally or non-invasive therapeutic options was performed in February and June 2020 using the MEDLINE, EMBASE and Cochrane databases. The search terminology was constructed using the name of the specific ASD or therapy option and the term 'status epilepticus' with the use of Boolean operators, e.g. "(brivaracetam) AND (status epilepticus)". The respective Medical Subject Headings (MeSH) and Emtree terms were used, if available. There is currently no level 1, grade A evidence for the use of ASDs in RSE. The best evidence was found for the use of lacosamide and topiramate (level 3, grade C), followed by brivaracetam, perampanel (each level 4, grade D) and stiripentol, oxcarbazepine and zonisamide (each level 5, grade D). Regarding non-medicinal options, there is little evidence for the use of the ketogenic diet (level 4, grade D) and magnesium sulfate (level 5, grade D) in RSE. The broad use of immunomodulatory or immunosuppressive treatment options in the absence of a presumed autoimmune etiology cannot be recommended; however, if an autoimmune etiology is assumed, steroid pulse, intravenous immunoglobulins and plasma exchange/plasmapheresis should be considered (level 4, grade D). Even if several studies suggested that the use of neurosteroids (level 5, grade D) is beneficial in RSE, the current data situation indicates that there is formal evidence against it. RSE in patients undergoing LOT or in a PCS represents a challenge for modern clinicians and epileptologists. The evidence for the use of ASDs in RSE beyond that in current guidelines is low, but several effective and well-tolerated options are available that should be considered in this patient population. More so than in any other population, advance care planning, advance directives, and medical ethical aspects have to be considered carefully before and during therapy.
Sections du résumé
BACKGROUND
Refractory status epilepticus (RSE) represents a serious medical condition requiring early and targeted therapy. Given the increasing number of elderly or multimorbid patients with a limitation of life-sustaining therapy (LOT) or within a palliative care setting (PCS), guidelines-oriented therapy escalation options for RSE have to be omitted frequently.
OBJECTIVES
This systematic review sought to summarize the evidence for fourth-line antiseizure drugs (ASDs) and other minimally or non-invasive therapeutic options beyond guideline recommendations in patients with RSE to elaborate on possible treatment options for patients undergoing LOT or in a PCS.
METHODS
A systematic review of the literature in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, focusing on fourth-line ASDs or other minimally or non-invasive therapeutic options was performed in February and June 2020 using the MEDLINE, EMBASE and Cochrane databases. The search terminology was constructed using the name of the specific ASD or therapy option and the term 'status epilepticus' with the use of Boolean operators, e.g. "(brivaracetam) AND (status epilepticus)". The respective Medical Subject Headings (MeSH) and Emtree terms were used, if available.
RESULTS
There is currently no level 1, grade A evidence for the use of ASDs in RSE. The best evidence was found for the use of lacosamide and topiramate (level 3, grade C), followed by brivaracetam, perampanel (each level 4, grade D) and stiripentol, oxcarbazepine and zonisamide (each level 5, grade D). Regarding non-medicinal options, there is little evidence for the use of the ketogenic diet (level 4, grade D) and magnesium sulfate (level 5, grade D) in RSE. The broad use of immunomodulatory or immunosuppressive treatment options in the absence of a presumed autoimmune etiology cannot be recommended; however, if an autoimmune etiology is assumed, steroid pulse, intravenous immunoglobulins and plasma exchange/plasmapheresis should be considered (level 4, grade D). Even if several studies suggested that the use of neurosteroids (level 5, grade D) is beneficial in RSE, the current data situation indicates that there is formal evidence against it.
CONCLUSIONS
RSE in patients undergoing LOT or in a PCS represents a challenge for modern clinicians and epileptologists. The evidence for the use of ASDs in RSE beyond that in current guidelines is low, but several effective and well-tolerated options are available that should be considered in this patient population. More so than in any other population, advance care planning, advance directives, and medical ethical aspects have to be considered carefully before and during therapy.
Identifiants
pubmed: 32705422
doi: 10.1007/s40263-020-00747-z
pii: 10.1007/s40263-020-00747-z
pmc: PMC8316215
doi:
Substances chimiques
Anticonvulsants
0
Immunoglobulins, Intravenous
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
801-826Commentaires et corrections
Type : ErratumIn
Références
Seizure. 2015 Nov;32:100-8
pubmed: 26552572
Brain. 2011 Oct;134(Pt 10):2802-18
pubmed: 21914716
Crit Care Med. 2020 Aug;48(8):1188-1195
pubmed: 32697490
Ann Neurol. 2017 Sep;82(3):342-352
pubmed: 28779545
Seizure. 2019 Jul;69:92-98
pubmed: 31004927
J Neurol. 2011 Feb;258(2):218-22
pubmed: 20803213
Anaesth Intensive Care. 2010 Sep;38(5):962
pubmed: 20865897
Epilepsia. 2001 Nov;42(11):1461-7
pubmed: 11879350
Acta Med Port. 2018 Oct 31;31(10):598-605
pubmed: 30387431
Orv Hetil. 2016 Apr 24;157(17):669-74
pubmed: 27084441
J Clin Epidemiol. 2011 Apr;64(4):401-6
pubmed: 21208779
Ann Indian Acad Neurol. 2015 Apr-Jun;18(2):256-7
pubmed: 26019434
Seizure. 2015 Feb;25:32
pubmed: 25645632
Case Rep Crit Care. 2019 Sep 02;2019:3218231
pubmed: 31565443
Ann Acad Med Singap. 2005 Aug;34(7):417-20
pubmed: 16123813
Pediatr Neonatol. 2015 Dec;56(6):429-31
pubmed: 26051033
BMC Med. 2017 May 18;15(1):102
pubmed: 28514961
J Obstet Gynaecol Res. 2019 Sep;45(9):1948-1951
pubmed: 31270892
Clin Neuropharmacol. 2005 Sep-Oct;28(5):243-4
pubmed: 16239766
Pediatr Neurol Briefs. 2017 Nov;31(3):8
pubmed: 29184380
Epilepsy Behav. 2015 Jun;47:17-23
pubmed: 26010959
Eur J Neurol. 2010 Mar;17(3):348-55
pubmed: 20050893
Neurocrit Care. 2011 Dec;15(3):519-24
pubmed: 21523523
Crit Care Med. 2019 Aug;47(8):1106-1115
pubmed: 31135501
Neurocrit Care. 2011 Jun;14(3):348-53
pubmed: 21249530
J Child Neurol. 2015 Feb;30(2):259-66
pubmed: 24464515
Eur J Paediatr Neurol. 2013 Nov;17(6):531-6
pubmed: 23751291
Neurology. 2020 Jan 14;94(2):e217-e224
pubmed: 31882532
Acta Neurol Scand. 2011 Feb;123(2):137-41
pubmed: 20868429
Epilepsia. 2012 Apr;53(4):761-2
pubmed: 22462573
Epilepsy Behav. 2015 Apr;45:176-9
pubmed: 25819947
Seizure. 2013 Jun;22(5):403-8
pubmed: 23518162
Seizure. 2016 May;38:7-10
pubmed: 27039016
Epilepsia. 2015 Oct;56(10):1515-23
pubmed: 26336950
Curr Neurol Neurosci Rep. 2015 Oct;15(10):66
pubmed: 26299274
JAMA Intern Med. 2020 Jan 1;180(1):172
pubmed: 31682677
Clin Neuropharmacol. 1988 Dec;11(6):537-44
pubmed: 3148367
Neurology. 2000 Jun 13;54(11):2163-5
pubmed: 10851386
J Pain Symptom Manage. 2018 Apr;55(4):1216-1223
pubmed: 29410071
Epilepsia. 2011 Oct;52 Suppl 8:53-6
pubmed: 21967364
N Engl J Med. 2019 Nov 28;381(22):2103-2113
pubmed: 31774955
Seizure. 2013 Jan;22(1):77-9
pubmed: 23127776
Seizure. 2016 Dec;43:61-68
pubmed: 27888743
Expert Rev Clin Pharmacol. 2017 Oct;10(10):1103-1108
pubmed: 28715945
Case Rep Neurol Med. 2019 Apr 9;2019:8537815
pubmed: 31093391
Seizure. 2016 Dec;43:14-22
pubmed: 27792912
Acta Neurol Scand. 2018 Sep;138(3):259-262
pubmed: 29633241
Crit Care Med. 2012 Sep;40(9):2677-84
pubmed: 22732291
Seizure. 2017 Jan;44:65-73
pubmed: 27890484
CNS Drugs. 2017 Jan;31(1):65-74
pubmed: 27896706
Indian J Crit Care Med. 2018 Apr;22(4):249-262
pubmed: 29743764
Epilepsia. 2018 Oct;59 Suppl 2:234-242
pubmed: 30043411
Pharmacotherapy. 2019 Mar;39(3):297-316
pubmed: 30723940
Epilepsy Behav. 2011 Feb;20(2):392-4
pubmed: 21190901
J Neuroimmunol. 2018 Oct 15;323:119-124
pubmed: 30196824
Epilepsy Curr. 2016 Jan-Feb;16(1):48-61
pubmed: 26900382
Seizure. 2017 Feb;45:172-180
pubmed: 28068584
Epilepsy Behav Case Rep. 2018 Jun 20;10:61-64
pubmed: 30073144
Epilepsy Res. 2019 Jan;149:88-91
pubmed: 30530123
Neurology. 2020 Mar 24;94(12):541-546
pubmed: 32107326
Neurobiol Dis. 2017 Aug;104:41-49
pubmed: 28461248
Front Neurol. 2019 Apr 26;10:423
pubmed: 31105638
Front Neurol. 2018 Jul 23;9:569
pubmed: 30083127
Ann Indian Acad Neurol. 2015 Jul-Sep;18(3):364-5
pubmed: 26425029
Epilepsia. 2010 Oct;51(10):2033-7
pubmed: 20813015
Epilepsy Behav. 2019 Dec;101(Pt B):106288
pubmed: 31133511
Epilepsy Res. 2012 Feb;98(2-3):232-7
pubmed: 22000869
Epilepsia. 2012 Jan;53(1):101-10
pubmed: 22191582
Appl Health Econ Health Policy. 2019 Oct;17(5):707-722
pubmed: 31161366
Neurocrit Care. 2019 Jun;30(3):652-657
pubmed: 30484010
Br J Clin Pharmacol. 2009 Nov;68(5):655-61
pubmed: 19916989
Expert Rev Clin Pharmacol. 2015;8(6):733-40
pubmed: 26436331
J Perinatol. 2009 Mar;29(3):252-3
pubmed: 19240731
Seizure. 2015 Jan;24:114-7
pubmed: 25458103
Arch Pediatr. 2014 Jun;21(6):620-3
pubmed: 24832126
Expert Rev Clin Pharmacol. 2016 Dec;9(12):1533-1546
pubmed: 27825017
Epilepsia. 2019 Aug;60(8):1593-1601
pubmed: 31260101
Seizure. 2013 Jan;22(1):70-3
pubmed: 23068971
J Child Neurol. 2005 Mar;20(3):239-41
pubmed: 15832617
Epilepsia. 2011 Oct;52(10):e148-52
pubmed: 21801171
Epilepsia. 2019 May;60(5):911-920
pubmed: 30980677
Seizure. 2011 Jun;20(5):428-30
pubmed: 21354831
Epilepsia. 2018 Feb;59(2):297-314
pubmed: 29270989
Epilepsia. 1991 Sep-Oct;32(5):712-5
pubmed: 1915181
Neurol Res Int. 2018 Jun 10;2018:8432859
pubmed: 29984000
J Neurol. 2013 Dec;260(12):3122-8
pubmed: 24122063
Epilepsia. 2018 Aug;59(8):1549-1556
pubmed: 29943451
Epilepsy Res. 2018 May;142:100-105
pubmed: 29609074
Neurology. 2001 Jan 23;56(2):248-50
pubmed: 11160964
Epilepsia. 2017 Apr;58(4):522-530
pubmed: 28276060
Drugs. 2018 Mar;78(3):307-326
pubmed: 29368126
J Epilepsy Res. 2011 Dec 30;1(2):52-6
pubmed: 24649446
Soc Work. 2011 Apr;56(2):119-28
pubmed: 21553575
J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619848816
pubmed: 31104535
Ann Clin Transl Neurol. 2017 Apr 26;4(6):411-414
pubmed: 28589168
Neurocrit Care. 2019 Aug;31(1):24-29
pubmed: 30891695
Neurocrit Care. 2014 Jun;20(3):484-8
pubmed: 23896816
Epidemiology. 2011 Jan;22(1):128; author reply 128
pubmed: 21150360
CNS Drugs. 2012 Sep 1;26(9):761-72
pubmed: 22823481
Can J Neurol Sci. 2012 Sep;39(5):660-3
pubmed: 22931712
Mult Scler Relat Disord. 2019 Jan;27:91-94
pubmed: 30347340
J Neurol. 2008 Jan;255(1):112-6
pubmed: 18204804
Epileptic Disord. 2018 Aug 1;20(4):301-312
pubmed: 30095075
Epileptic Disord. 2012 Dec;14(4):438-41
pubmed: 23248042
Clin Nutr ESPEN. 2015 Oct;10(5):e199-e200
pubmed: 28531521
Acta Neurol Scand. 2011 Feb;123(2):142-6
pubmed: 21198444
BMJ Case Rep. 2015 Aug 04;2015:
pubmed: 26243746
Expert Opin Pharmacother. 2019 Oct;20(14):1755-1765
pubmed: 31264486
Neuropharmacology. 2009 Jan;56(1):190-7
pubmed: 18585399
Pediatr Neurol. 2014 Apr;50(4):407-10
pubmed: 24630284
Neurocrit Care. 2013 Feb;18(1):89-92
pubmed: 23090840
Ann Dermatol Venereol. 2014 Aug-Sep;141(8-9):523-7
pubmed: 25209816
Epilepsia. 2011 Nov;52(11):1956-65
pubmed: 21883180
Epilepsia. 2016 Dec;57(12):2056-2066
pubmed: 27753082
Epilepsy Res. 2018 Aug;144:1-6
pubmed: 29727818
J Neurol Sci. 2017 Feb 15;373:35-37
pubmed: 28131220
Mov Disord. 2013 Jun;28(6):820-2
pubmed: 23720271
Epilepsy Behav. 2018 Sep;86:179-186
pubmed: 30076046
Eur J Paediatr Neurol. 2018 Jan;22(1):182-185
pubmed: 29203057
Rev Neurol (Paris). 2008 Feb;164(2):194-9
pubmed: 18358881
Med Ref Serv Q. 2019 Apr-Jun;38(2):171-180
pubmed: 31173570
Brain Dev. 2019 May;41(5):420-427
pubmed: 30638692
Epilepsy Behav Case Rep. 2014 Nov 27;2:199-202
pubmed: 25667907
Epilepsia. 2017 Apr;58(4):512-521
pubmed: 28276062
Epilepsia. 2018 Oct;59 Suppl 2:243-248
pubmed: 30159874
Seizure. 2013 Dec;22(10):905-7
pubmed: 23953988
Acta Neurol Scand. 2019 Apr;139(4):369-376
pubmed: 30613951
CNS Drugs. 2013 Apr;27(4):321-9
pubmed: 23533010
Drugs. 2015 Sep;75(13):1499-521
pubmed: 26310189
Epilepsy Res. 2017 Sep;135:38-42
pubmed: 28622537
Epilepsia. 2011 Nov;52(11):e181-4
pubmed: 22003821
Ann Pharmacother. 2011 Nov;45(11):1445-9
pubmed: 22010001
Seizure. 2011 Sep;20(7):529-32
pubmed: 21489827
Neuropediatrics. 2012 Aug;43(4):209-16
pubmed: 22911482
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Child Neurol Open. 2015 Mar 23;2(1):2329048X14550067
pubmed: 28503584
Childs Nerv Syst. 2011 Sep;27(9):1425-30
pubmed: 21442269
Epilepsia Open. 2016 Jul 27;1(1-2):9-21
pubmed: 29588925
Seizure. 2013 Sep;22(7):581-3
pubmed: 23597842
Ann Neurol. 2014 Dec;76(6):911-5
pubmed: 25363147
Brain. 2012 Aug;135(Pt 8):2314-28
pubmed: 22577217
Epilepsy Behav Case Rep. 2019 Feb 07;11:92-95
pubmed: 30834194
Epilepsia. 2017 Jun;58(6):933-950
pubmed: 28295226
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
Front Neurol. 2018 Aug 02;9:595
pubmed: 30116217
Neurocrit Care. 2012 Aug;17(1):3-23
pubmed: 22528274
Epilepsia. 2018 Oct;59 Suppl 2:228-233
pubmed: 30043427
Neurocrit Care. 2012 Apr;16(2):294-8
pubmed: 22203547
Epilepsy Behav. 2017 May;70(Pt A):177-181
pubmed: 28427029
Rinsho Shinkeigaku. 2014;54(9):715-20
pubmed: 25283825
Eur J Clin Nutr. 2019 Dec;73(12):1594-1597
pubmed: 31316173
J Neurol Sci. 2014 Jan 15;336(1-2):276-80
pubmed: 24210076
Seizure. 2016 Oct;41:62-5
pubmed: 27475280
Pediatr Neurol. 2015 Apr;52(4):442-5
pubmed: 25771999
Epilepsy Behav. 2003 Dec;4(6):757-60
pubmed: 14698713
Epilepsia. 2011 Oct;52 Suppl 8:28-30
pubmed: 21967356
Arq Neuropsiquiatr. 2011 Jun;69(3):565-6
pubmed: 21755142
Rev Med Chil. 2009 Jul;137(7):936-9
pubmed: 19802423
Epilepsy Behav. 2014 Jul;36:144-52
pubmed: 24922617
Pediatr Neonatol. 2019 Aug;60(4):417-422
pubmed: 30449706
Seizure. 2013 Apr;22(3):217-20
pubmed: 23333762
Neurologist. 2011 Nov;17(6):325-9
pubmed: 22045283
Seizure. 2013 Sep;22(7):553-9
pubmed: 23643626
Lancet Neurol. 2006 Mar;5(3):246-56
pubmed: 16488380
Epilepsy Behav. 2015 Aug;49:354-8
pubmed: 25962657
Brain Stimul. 2019 Jul - Aug;12(4):835-844
pubmed: 31053521
Epilepsy Behav. 2019 Dec;101(Pt B):106413
pubmed: 31371204
Epilepsia. 2019 Dec;60(12):2448-2458
pubmed: 31713232
Epilepsy Behav. 2018 Jul;84:93-98
pubmed: 29758445
CNS Drugs. 2018 Nov;32(11):997-1009
pubmed: 30232735
Acta Neurol Scand. 2018 Jan;137(1):67-75
pubmed: 28832891
Brain Dev. 2011 Sep;33(8):687-91
pubmed: 21075572
Clin Neurophysiol Pract. 2017 Jul 01;2:154-160
pubmed: 30214989
Epilepsia. 2012 Jun;53(6):935-46
pubmed: 22612290
Seizure. 2012 Apr;21(3):198-201
pubmed: 22244046
Acta Neurol Scand. 2015 Dec;132(6):435-9
pubmed: 25809474
Rev Neurol. 2012 Jul 1;55(1):20-5
pubmed: 22718405
Epilepsy Behav. 2020 Aug;109:107139
pubmed: 32417381
Pediatr Neurol. 2016 Aug;61:83-6
pubmed: 27241232
Seizure. 2019 May;68:89-96
pubmed: 30245007
Neurocrit Care. 2017 Apr;26(2):273-279
pubmed: 27844464
Eur J Paediatr Neurol. 2014 Sep;18(5):604-8
pubmed: 24836405
Brain Stimul. 2019 Sep - Oct;12(5):1101-1110
pubmed: 31126871
Neurocrit Care. 2006;4(1):35-46
pubmed: 16498194
Neurology. 2014 Feb 25;82(8):665-70
pubmed: 24453083
Ther Adv Neurol Disord. 2017 Feb;10(2):103-126
pubmed: 28382109
Epilepsia. 2003 Oct;44(10):1353-6
pubmed: 14510830
Neurology. 2013 Aug 20;81(8):770-1
pubmed: 23873972
Drugs. 2017 Jan;77(1):67-74
pubmed: 28004305
Epileptic Disord. 2014 Dec;16(4):486-93
pubmed: 25465280
Int J Obstet Anesth. 2016 May;26:71-5
pubmed: 26775897
Expert Rev Clin Pharmacol. 2018 Mar;11(3):309-324
pubmed: 29285947
Neurology. 2017 Mar 7;88(10):938-943
pubmed: 28179470
Acta Neurol Scand. 2017 Jan;135(1):92-99
pubmed: 27080243
BMJ Case Rep. 2017 Aug 1;2017:
pubmed: 28765179
Epilepsia. 2017 Sep;58(9):1533-1541
pubmed: 28681418
Epilepsia. 2006 Jun;47(6):1070-1
pubmed: 16822255
Neuropediatrics. 2017 Feb;48(1):45-48
pubmed: 27434885
Mol Clin Oncol. 2016 Dec;5(6):845-849
pubmed: 28101360
J Neurol Neurosurg Psychiatry. 1991 Sep;54(9):845-6
pubmed: 1955910
Expert Rev Clin Pharmacol. 2016;9(5):637-45
pubmed: 26891946
Seizure. 2016 Jul;39:5-9
pubmed: 27161669
Epilepsia. 2010 Jun;51(6):1083-5
pubmed: 19845731
J Pediatr Pharmacol Ther. 2014 Oct-Dec;19(4):317-24
pubmed: 25762878
Epilepsy Behav. 2018 Jun;83:28-35
pubmed: 29649671
Acta Neurol Scand. 2012 Feb;125(2):e7-e11
pubmed: 21711264
Clin Drug Investig. 2015 Jul;35(7):463-9
pubmed: 26108190
Seizure. 2017 Oct;51:1-5
pubmed: 28743048
Seizure. 2003 Sep;12(6):379-87
pubmed: 12915084
Acta Neurol Scand. 2018 Apr;137(4):432-437
pubmed: 29313881
Crit Care Med. 2015 May;43(5):1003-9
pubmed: 25654177
Epilepsy Res. 2014 Dec;108(10):1912-6
pubmed: 25454503
Acta Neurol Scand. 2014 May;129(5):294-9
pubmed: 23937330
J Child Neurol. 2001 Feb;16(2):147-50
pubmed: 11292225
J Neurol. 2014 Apr;261(4):663-7
pubmed: 24390201
Front Neurol. 2017 Sep 26;8:507
pubmed: 29018404
Seizure. 2014 Feb;23(2):151-4
pubmed: 24295895
Epilepsy Behav. 2018 Dec;89:89-93
pubmed: 30390435
J Clin Diagn Res. 2017 Jul;11(7):ED33-ED34
pubmed: 28892919
Drug Metab Rev. 2007;39(4):647-57
pubmed: 18058328
Epilepsia. 2018 Oct;59 Suppl 2:220-227
pubmed: 29453777
Epileptic Disord. 2015 Dec;17(4):491-5
pubmed: 26610306